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Background: MicroRNA (miR)-21 has been revealed as an oncogene in cancer development, and is one of the
miRNAs closely connected to angiogenesis. We aimed to explore the impact of miR-21 expression in both tumor
and stromal compartments of non-small cell lung cancer (NSCLC), and correlations between miR-21 and angiogenic
protein markers.
Methods: From 335 unselected stage I to IIIA NSCLC carcinomas, duplicate tumor and tumor-associated stromal
cores were collected in tissue microarrays (TMAs). In situ hybridization (ISH) was used to detect the expression of
miR-21 separately in tumor cells and stromal cells of the tumor, and immunohistochemistry (IHC) was used to
detect the expression of the protein markers protein kinase B (Akt), phosphatidylinositol-3-kinase (PI3K), hypoxia
induced factor 1 (HIF1α) and vascular endothelial growth factor-A (VEGF-A).
Results: In univariate analyses, high tumor cell expression of miR-21 in patients with lymph node metastasis was a
positive prognostic factor (P = 0.024). High stromal miR-21 expression had a negative prognostic impact (P = 0.022).
In the multivariate analysis, low tumor mir-21 expression in node positive patients was an independent adverse
prognostic factor (HR 2.03, CI 95% 1.09-3.78, P = 0.027).
Conclusions: In patients with lymph node metastasis, miR-21 expression in tumor cells is an independent positive
prognostic factor. High stromal miR-21 expression is a negative prognostic factor.
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Lung cancer is the leading cause of cancer-related
deaths. NSCLC accounts for 80-85% of all lung cancers.
New treatment strategies have so far had limited effect
on lung cancer mortality [1]. Hence, research to identify
new possible treatment targets is pivotal.
MicroRNAs (miRNAs) are small (19-22 nucleotides)
non-coding RNAs. They play an important role in differ-
ent cellular processes, such as regulation of proliferation,
differentiation, apoptosis, development, metabolism,
stress response and immunity [2,3]. It is assumed that* Correspondence: Helge.Stenvold@uit.no
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reproduction in any medium, provided the orapproximately 30% of the genes are regulated by miR-
NAs [3]. The accruing prognostic data on miRNAs has
made them interesting as potential therapeutic targets.
Novel agents have not yet reached clinical trials, but
there is considerable research going on in this field [4].
miR-21 is one of the most thoroughly studied miR-
NAs. Studies have revealed miR-21 as an oncogene [5],
and in a recent meta-analysis miR-21 appeared as a
negative prognostic factor [2]. It is also one of the miR-
NAs closely connected to angiogenesis [6,7]. In a recent
study [8], we screened tissues from 10 worst and 10 best
prognosis NSCLC cases as well as 10 controls for the ex-
pression of several angiogenesis-related miRNAs. miR-
21 was significantly up-regulated in tumor versus nor-
mal tissue, and was among the miRNAs with the largest
expression difference between tumor tissue and normalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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angiogenesis suggest both pro- and antiangiogenic prop-
erties [9,10], the involved mechanisms remains to be
further investigated.
In our screening study [8] there was a four-fold change
in tumor when compared to normal tissue when quanti-
fied by microarray hybridization and validated by real-
time qPCR, but there was no significant difference
between expressions in poor versus good prognostic
cases. In fact, previously published results on the prog-
nostic impact of miR-21 have been conflicting [11-15].
In cancer, the tumor stroma is, in addition to tumor
cells, an important player in cancer development. Ac-
cordingly, miRNAs can be expressed differentially in
tumor cells than in the surrounding stroma, and one
speculate if its impact on prognosis could be different in
the two compartments [16,17]. To further explore the
prognostic impact of miR-21 in NSCLC we used ISH to
facilitate, for the first time, evaluation of specific miR-21
expression in tumor cells and tumorsurrounding stromal
cells, respectively.
In this study we aimed to investigate the prognostic
impact of miR-21 in a large unselected NSCLC popula-
tion. Since the impact of various angiogenic protein
markers have been investigated in this cohort [18-20],
we have also assessed the association between miR-21
and angiogenic markers.
Methods
Patients and clinical samples
Between 1990 and 2004, 371 patients with pathological
stage I to IIIA non-small cell lung cancer were diag-
nosed at the University Hospital of North Norway and
Nordland Central Hospital. Resected tissues from the
primary tumors in these patients were used in our retro-
spective study. Out of 371 patients, 36 were excluded
from the study due to radiotherapy or chemotherapy
prior to surgery (n = 10), other malignancy within 5
years before NSCLC diagnosis (n = 13) or inadequate
paraffin-embedded fixed tissue blocks (n = 13). Adjuvant
chemotherapy was not introduced in Norway during this
period (1990 – 2004). Thus, 335 patients with complete
demographic and clinicopathological data were eligible
for this study.
This report includes follow-up data as of January 10,
2011. The median follow-up time of survivors was 105
months (range 73-234). Formalin-fixed, paraffin-embedded
tumor specimens were obtained from the archives of
the Departments of Clinical Pathology at the University
Hospital of North Norway and Nordland Central Hospital.
The pathological data were revised according to the 7th
edition of UICC TNM classification of lung cancer [21].
The National Data Inspection Board and the Regional
Committee for Research ethics approved this study.Microarray construction
We used a 0.6 mm-diameter stylet to sample two cores
with neoplastic tissue and two cores with tumor stro-
ma from different areas of the primary tumors from
each patient. The tumor stroma consists of the non-
malignant cells of the tumor; activated fibroblasts, spe-
cialized mesenchymal cell types, innate and adaptive
immune cells and the vasculature with endothelial cells
and pericytes, as well as the extracellular matrix (ECM).
Normal lung tissue localized distant from the tumor and
lung tissue sample from 20 patients without cancer diag-
nosis were used as controls. The TMAs were assembled
using a tissue-arraying instrument (Beecher Instruments,
Silver Springs, MD, US). Eight tissue microarray blocks
were made to include all the tissue samples. Multiple
4-μm-sections were cut with a Micron microtome
(HM355S) and stained by specific antibodies for immu-
nohistochemical analyses. The detailed methodology has
been previously reported [20].
In situ hybridization (ISH)
In situ hybridization was performed following the proto-
col developed by Exiqon, Vedbaek, Denmark [22].
Digoxigenin (DIG) labeled locked nucleic acid (LNA)
modified probes from Exiqon for miR-21 (hsa-miR-21),
positive control (U6, hsa/mmu/rno) and negative control
(scramble-miR) from Kit 2, miR-21, (90002, Exiqon)
were used in this study. Some adjustments were done to
get a specific and sensitive detection of miRNA in our
sections from formalin-fixed paraffin-embedded (FFPE)
TMA blocks.
We placed 4 μm sections of the TMA blocks in a
heater at 59°C over night to attach cores to Super Frost
Plus slides. Sections were deparaffinised with xylene (3 ×
5 min.) and then rehydrated with ethanol solutions
(99.9% - 96% - 70%) ending up in PBS, pH 7.4.
Proteinase-K (20 μg/ml) (Exiqon, Vedbaek, Denmark)
treatment was done in PK-buffer (5 mM Tris.HCl, pH
7.5, 1 mM EDTA, 1 mM NaCl, autoclaved) at 37°C for
20 min in a HYBrite automated hybridizer (Abbot la-
boratories, IL, US). After a PBS wash the sections were
dehydrated through increasing gradient of ethanol solu-
tions and air-dried. The LNA-probes were denatured by
heating to 90°C for 4 min. Hybridization of the LNA-
probe miR-21 (50 nM) and scramble miR (50 nM) con-
trol was carried out in the HYBrite automated hybridizer
at 50°C for 60 min. The positive control U6 (1 nM) was
hybridized at 55°C for 60 min. Stringent washes was
performed in pre-heated SSC buffers, 1 × 5 min in 5×
SSC and 2 × 5 min in 1× SSC and 0,2× SSC. Sections
were blocked against unspecific binding in blocking
solution from DIG wash and Block Buffer set (Roche,
Mannheim, Germany) for 15 min at room temperature
(RT). Alkaline phosphatase (AP)-conjugated anti-DIG
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munologic detection. After PBS-T wash the substrate
enzymatic reaction was carried out with NBT/BCIP
(Roche) at 30°C in the hybridizer for 120 min. The reac-
tion was stopped with a 2 × 5 min wash in KTBT buffer
(50 mM Tris-Hcl, 150 mM NaCl, 10 mM KCl). Counter
stain with nuclear fast red (WALDECK, ZE-012-250)
was done at RT for 1 min and then rinsed in tap water,
dehydrated through increasing gradient of ethanol solu-
tions and mounted with Histokitt mounting medium
(Assistant-Histokitt, 1025/250).
Immunohistochemistry (IHC)
The detailed p-Akt Thr308 (rabbit monoclonal, clone
736E311, #4056, Cell Signaling Technology, 1:50), Akt2
(rabbit monoclonal, clone 54G8, #4057, Cell Signaling
Technology, 1:18), Akt3 (rabbit polyclonal, #4059, Cell
Signaling Technology, 1:8), PI3K (rabbit polyclonal,
#4254, Cell Signaling Technology, 1:25), HIF1α (mouse
monoclonal, NB100-131, Novus Biological, 1:35000), and
VEGF-A (rabbit polyclonal, RB-1678, Neomarkers, 1:10)
IHC procedures has been previously published [18-20].
For each antibody, including negative controls, the TMA
staining were done in a single experiment.
Scoring of ISH and IHC
The ARIOL imaging system (Genetix, San Jose, CA) was
used to scan the TMA slides of ISH staining. The slides
were loaded in the automated loader (Applied Imaging
SL 50) and specimens were scanned at low (1.25×) and
high (20×) resolution using the Olympus BX 61 micro-
scope with automated platform (Prior). Representative and
viable tissue sections were scored manually and semiquan-
titatively for cytoplasmic staining on a computer screen.
The dominating staining intensity in tumor cells was scored
as: 0 = negative; 1 = weak; 2 = intermediate; 3 = strong
(Figure 1). The tumor-related stroma was scored with
one value from 0-3 based on both staining intensity and
cell density. We summarized the scores from tumor cells
and stroma to get a total score which may be comparable
to findings in other studies using RT-qPCR, where it not is
discriminated between tumor and stromal expression. All
cores were anonymized and independently scored by 2 ex-
perienced pathologists (S.A.S. and A.V.). When assessing a
variable for a given core, the observers were blinded to the
scores of the other observer and to outcome. In case of
disagreement (score discrepancy > 1), the slides was re-
examined and a consensus was reached by the observers.
Mean score for each case was calculated from all 4
cores and both examiners. High expression of miR-21 in
tumor cells was defined as a mean score ≥ 0.5. For
stroma, high expression was defined as positive values
(>0). For the angiogenic protein markers, the same cut-
off values as previously published was used [18-20].Statistical methods
All statistical analyses were performed using the statistical
package SPSS (Chicago, IL), version 19.0. The chi-square
test and the Fisher exact test were used to examine the
association between molecular marker expression and
the clinicopathological markers. Correlations between
markers were assessed using Spearman’s rank correl-
ation. Plots of disease-specific survival (DSS) according
to marker expression were drawn using Kaplan-Meier
method, and statistical significance between survival
curves was assessed by the log rank test. Variables of
significant value from the univariate analyses were en-
tered into multivariate analysis using the backward step-




Demographic, clinical and histopathological variables are
listed in Table 1. The median patient age was 67 (range
28-85) and the majority were male (76%). Most (95%)
were current or previous smokers. The NSCLC tumors
comprised 191 squamous cell carcinomas (SCCs), 113
adenocarcinomas (ACs) including 18 bronchioalveolar
carcinomas (BACs) and 31 large-cell carcinomas (LCCs).
Expression of miR-21 and correlations
miR-21 was expressed in the cytoplasm of tumor cells.
The staining was mainly diffuse and partly granular. In
tumor stroma, inflammatory cells, pneumocytes, fibro-
blasts and endothelial cells also showed mainly diffuse
cytoplasmic staining.
There were no significant correlations between miR-21
and the angiogenesis-related markers Akt, PI3K, HIF1α
or VEGF-A. Neither were there any significant correla-
tions when stratifying for nodal status (Table 2).
Univariate analysis
As shown in Table 1, the clinicopathological variables per-
formance status (P = 0.016), histology (P = 0.028), tumor
differentiation (P < 0.001), surgical procedure (P = 0.007),
pathological stage (P < 0.001), tumor status (P < 0.001),
nodal status (P < 0.001) and vascular infiltration (P = 0.001)
were significant prognostic indicators for DSS.
The survival analysis for miR-21 is presented in Table 3
and Figure 2. Expression of miR-21 in the total cohort
based on both tumor and stromal cells had no signifi-
cant prognostic impact.
The situation was the same when only tumor cells were
assessed. In subgroup analyses of lymph node positive pa-
tients, however, a high tumor miR-21 expression was sig-
nificantly associated with an improved prognosis when
compared to low expression (P = 0.024). This was not ob-
served in lymph node negative patients (P = 0.091).
Figure 1 In situ hybridization (ISH) analysis of non-small-cell lung cancer. Scoring intensities based on blue cytoplasmatic staining graded
from 0-3 differentiated in tumor cells and stroma of adenocarcinoma and squamous cell carcinoma are shown.
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a negative prognostic indicator (P = 0.022). This was also
observed in the subgroup with node-negative disease,
but not in node-positive patients.
Multivariate analysis
In the multivariate analysis the following clinicopatho-
logical variables appeared as independent prognostic
variables: performance status (P = 0.008), histology (P =
0.001), tumor differentiation (P = 0.007), tumor status
(P = 0.007), nodal status (P = 0.022) and vascular infiltra-
tion (P = 0.004).
Results of the multivariate analyses for miR-21 expres-
sion are presented in Table 3. In analyses of the total
material, all significant clinicopathological factors from
the univariate analyses were included. For the N + sub-
group, no relevant clinicopathological factors were sig-
nificant in the univariate analysis. Tumor or stromal
miR-21 expression in the total material had no inde-
pendent prognostic impact. In node positive patients,
however, low tumor miR-21 expression was an inde-
pendent negative prognostic factor (HR 2.03, CI 95%
1.09-3.78, P = 0.027).
Discussion
In a large unselected cohort, we have used high-
throughput TMA-technique and in situ hybridization to
evaluate the prognostic impact of miR-21 expression in
tumor tissue and stroma of NSCLC. To our knowledge,
we are the first to use ISH to study miR-21 expressionand outcome in a large NSCLC cohort, facilitating ana-
lyses discriminating specifically between tumor cells and
cells of the tumor stroma. We find high tumor miR-21
expression in node-positive patients to be an independ-
ent positive prognostic indicator. In univariate analyses,
we find high stromal miR-21 expression to be a negative
prognostic factor in the total material and in node-
negative patients. There was no correlation between
miR-21 and angiogenesis-related markers.
miRNAs have a large impact on gene regulation, and
are considered major players in tumor development and
metastasis [3]. These nucleotides act as both oncogenes
and tumor suppressor genes, as they may be both up-
and down-regulated in tumors. miR-21 is known to be
abundantly expressed in a variety of cancers, and is in
many tumor types associated with a reduced overall sur-
vival [2]. In a recent array screening study, including 20
NSCLC patients and 10 controls, we found miR-21 to be
one of the most upregulated miRNAs in tumor tissue,
when compared to normal tissue, by both microarray
hybridization and quantitative real time polymerase
chain reaction (qRT-PCR) technique [8].
In recent years, a few studies have explored the
prognostic impact of miR-21 in NSCLC. Markou et al.
studied 48 patients, where 67% where in stage I/II and
33% stage III/IV. They found miR-21 to be an inde-
pendent negative prognostic factor for OS [13]. Gao
et al. observed the same in 47 NSCLC samples. In
their cohort, 47% were stage I, 25% stage II and 28%
stage III, respectively [11]. In three cohorts from
Table 1 Patient characteristics and their variables as
predictors for disease-specific survival in 335 NSCLC






survival % Pn (91)
Age
≤65years 156 (47) 98 55
0.42
>65 years 179 (53) NR 60
Sex
Female 82 (24) 190 64
0.22
Male 253 (76) 98 56
Smoking
Never 15 (5) 19 43
0.26Current 215 (64) NR 60
Former 105 (31) 84 55
Performance status
PS 0 197 (59) NR 63
0.016PS 1 120 (36) 64 52
PS 2 18 (5) 25 33
Weight loss
<10% 303 (90) 190 58
0.76
>10% 32 (10) 98 57
Histology
SCC 191 (57) NR 66
0.028Adenocarcinoma 113 (34) 54 46
LCC 31 (9) 98 56
Differentiation
Poor 138 (41) 47 47
<0.001Moderate 144 (43) 190 65
Well 53 (16) NR 68
Surgical procedure
Lobectomy + Wedge* 243 (73) 190 62
0.007
Pitunionectomy 92 (27) 37 47
Pathological stage
I 157 (47) NR 61
<0.001II 136 (40) 62 51
IIIa 42 (13) 17 23
Tumor status
1 85 (25) 190 75
<0.0012 188 (56) 84 57
3 62 (19) 25 36
Nodal status
0 232 (69) NR 67
<0.0011 76 (23) 35 43
2 27 (8) 18 18
Table 1 Patient characteristics and their variables as
predictors for disease-specific survival in 335 NSCLC
patients (univariate analyses; log-rank test) (Continued)
Surgical margins
Free 3)7 (92) 190 59
0.37
Not free 28 (8) 47 48
Vascular infiltration
No 284 (85) 190 62
0.001
Yes 51 (15) 27 33
*Wedge, n= 10.
Abbreviations: NR not reached, PS performance status, SCC squanos cell
carcinoma, LCC large-cell carcinoma.
Statistically significant results in bold font.
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III), Norway (57% stage I, 14% stage II, 29% stage III),
and Japan (74% stage I, 26% stage II), Saito and col-
leagues showed miR-21 to be an independent negative
prognostic factor. In the Norwegian and American ma-
terial, overall survival was the endpoint, while in the
Japanese cohort relapse free survival was [14]. Landi
and colleagues used an oligo array with 440 human
miRNAs to evaluate differences in miRNA expression
depending on histology and clinical outcome in 290
NSCLC tissues, constituted by 40% stage I, 29% stage
II, 26% stage III and 4% stage IV cancers. They found
miR-21 to differentiate between adenocarcinoma and
squamous cell carcinoma, but there was no difference
in survival according to miR-21 expression rate [12].
In a large study on 639 patients (35% stage I, 23%
stage II and 42% stage III), Voortman et al. observed
no prognostic impact of miR-21 on NSCLC survival.
There was a tendency towards a better prognosis for
high miR-21 expression, but this finding was not sig-
nificant (P = 0.06) [15].
There were some differences in methodology between
these studies, as fresh frozen tissue was used in three
[11,13,14] and paraffin-embedded material in two stud-
ies [12,15]. For quantification of miRNA, all except the
Landi study used qRT-PCR. In the studies where miR-21
was associated with a worse prognosis, subgroup ana-
lyses were not performed. The Landi and Gao studies
[11,12] were numerously too small and the Saito study
consisting of three cohorts (89, 37 and 189 patients re-
spectively) [14], was not suited for subgroup analyses.
Yang et al. performed a meta-analysis based on the
studies mentioned above. They also included two other
studies analyzing miR-21 in serum. The conclusion was
that high miR-21 expression was significantly associated
with poor survival [23].
When using the summarized score of tumor cell and
stromal expression in the whole cohort, miR-21 was
without any significant prognostic impact. In the stromal
Table 2 Correlations between miR-21 expression and angiogenesis related markers
Molecular marker Akt PI3K HIF1α VEGF-A
Compartment Tumor Stroma Tumor Stroma Tumor Stroma Tumor Stroma
A: Correlations in all 335 patients
miR-21 Tumor P = 0.700 P = 0.488 P = 0.687 P = 0.751
Stroma P = 0.217 P = 0.655 P = 0.251 P = 0.622
B: Correlations in 232 node-negative patients
miR-21 Tumor P = 0.736 P = 0.566 P = 0.473 P = 0.945
Stroma P = 0.692 P = 473 P = 0.685 P = 0.272
C: Correlations in 103 node-positive patients
miR-21 Tumor P=0.735 P=0.701 P=0.751 P=0.685
Stroma P=0.112 P=0.722 P=0.144 P=0.192
Table 3 miR-21 in tumor cells and stroma as predictors for disease-specific survival in NSCLC patients (univariate
analysis; log-rank test) and results of Cox regression analysis summarizing significant independent prognostic factors
Characteristics Pts (n) Pts (%) Median survival (months) 5-Year survival (%) Univariate (P) Multi-variate (P) HR 95% CI
Total (n = 335) 0.45 0.71 1.08
Low 220 66 190 61 0.73-1.60
High 98 29 98 55
Missing 17 5
Tumor1 (n = 335) 0.65 0.40 1.20
Low 60 18 NR 59 0.74-1.95
High 258 77 127 59
Missing 17 5
N0 (n = 223) 0.091 0.33 0.69
Low 43 19 NR 75 0.33-1.45
High 180 81 190 66
N+ (n = 95) 0.024 0.027 2.03
Low 17 18 17 18 1.09-3.78
High 78 82 37 42
Stroma2 (n = 335) 0.022 0.12 0.45
Low 21 6 189 89 0.16-1.24
High 301 90 127 57
Missing 13 4
N0 (n = 225) 0.044 0.061 0.32
Low 16 7 190 93 0.08-1.38
High 209 93 NR 66
N+ (n = 97) 0.44 0.45 0.58
Low 5 5 71 75 0.14-2.37
High 92 95 27 36
NR = not reached.
1Tumor cells.
2Cells of the peritumoral connective tissue (fibroblasts, mesenchymal cells, immune cells, endothelial cells, pericytes and extracellular matrix.
Statistically significant results in bold font.
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Figure 2 Disease-specific survival curves according to expression of A) miR-21 in stroma, B) miR-21 in tumor, C) miR-21 in tumor in
node negative patients and D) miR-21 in tumor in node positive patients.
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nosticator in univariate, but not in the multivariate ana-
lysis. In the studies mentioned above [11,13,14], except
for the studies by Voortman [15] and Landi [12], miR-21
appears to be a negative prognostic factor in NSCLC,
corroborating our stromal results. In contrast, we found
miR-21 expression in tumor cells to be an independent
positive prognostic factor in node positive lung cancer
patients. One may speculate if the differences we ob-
serve between our results and some of the other studies
are caused by the different methodologies used. As we
use ISH-technique, miR-21 expression can be assessed
separately in tumor and stromal cells. When using the
qRT-PCR method without prior microdissection, it
can not be differentiated between the tumor cells and
the stromal compartment. Gregg and colleagues per-
formed microdissection on a prostate cancer material to
separate tumor and stromal cells, and showed a large
difference regarding gene expression between the twocompartments [24]. Our findings show that there is a
prognostic difference in expression between the two
compartments. Using qRT-PCR the contribution of miR-
21 from the stromal compartment may override the con-
tribution from tumor cells, especially at significant dif-
ferences in expression. Consequently, the data will
reflect the situation in stroma, and a divergent situation
in the tumor cells will not be detected. The conclusion
in the Yang meta-analysis reflects the findings in these
studies, and does not take into account possible expres-
sion differences between the compartments.
The mechanistic functions of miR-21 are still being ex-
plored, but some functions have recently been suggested.
In human umbilical vein endothelial cells (HUVECs),
Sabatel and colleagues found miR-21 to be a potential
inhibitor of angiogenesis via inhibition of RhoB, resulting
in a reduction in endothelial proliferation, migration
and vessel formation [10]. On the other hand, Liu et al.
demonstrated miR-21 to induce angiogenesis in human
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VEGF and through activating the Akt and ERK pathways
[9]. Hence, miR-21 may have both pro- and anti-
angiogenic functions. Angiogenesis is an important trait
of cancer progression [25], and inhibiting angiogenesis
may contribute to slow down cancer growth. In the light
of these opposing findings and our data, we may specu-
late if miR-21 has opposite impacts in different stages of
the disease. Could high miR-21 in early stages (node-
negative) act pro-angiogenic and contribute to a faster
progression, while in a node positive stage, it acts anti-
angiogenic and protects against further progression?
We did not find any correlations between miR-21 and
angiogenic markers of pathways earlier described for
miR-21 and angiogenesis [9,10]. These pathways are pos-
sibly tissue and cell type specific. Studies exploring miR-
21 as a modulator of angiogenesis have in some cases
used endothelial cells in their models [10]. In our mater-
ial, we have not specifically studied endothelial cells,
so the connection between miR-21 and angiogenetic
markers seen in endothelial cells will not necessarily be
mirrored by our tissue samples as we assessed the sum
off all stromal cell types.
Conclusion
We found tumor cell miR-21 expression to be an inde-
pendent positive prognostic factor in node-positive
NSCLC. In the total material, stromal miR-21 expression
was a negative prognostic factor in univariate analysis.
We identified diverging impacts of miR-21 related to cell
compartment and nodal status. These findings should be
further explored, and may have implications for the fu-
ture use of miR-21 in diagnostics and therapy.
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